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Abstract: Cow’s milk allergy (CMA) is an early-onset allergy of which the underlying genetic
factors remain largely undiscovered. CMA has been found to co-occur with other allergies and
immunological hypersensitivity disorders, suggesting a shared genetic etiology. We aimed to
(1) investigate and (2) validate whether CMA children carry a higher genetic susceptibility for
other immunological hypersensitivity disorders using polygenic risk score analysis (PRS) and
prospective phenotypic data. Twenty-two CMA patients of the Dutch EuroPrevall birth cohort
study and 307 reference subjects were genotyped using single nucleotide polymorphism (SNP) array.
Differentially genetic susceptibility was estimated using PRS, based on multiple P-value thresholds
for SNP inclusion of previously reported genome-wide association studies (GWAS) on asthma,
autism spectrum disorder, atopic dermatitis, inflammatory bowel disease and rheumatoid arthritis.
These associations were validated with prospective data outcomes during a six-year follow-up in
19 patients. We observed robust and significantly higher PRSs of asthma in CMA children compared
to the reference set. Association analyses using the prospective data indicated significant higher PRSs
in former CMA patients suffering from asthma and related traits. Our results suggest a shared genetic
etiology between CMA and asthma and a considerable predictive sensitivity potential for subsequent
onset of asthma which indicates a potential use for early clinical asthma intervention programs.
Keywords: allergic march; cow’s milk allergy; genome-wide association; polygenic risk score
1. Background
Cow’s milk allergy (CMA) is among the most frequent food allergies in young children [1].
An exact incidence, however, is difficult to establish, since it has been shown that large discrepancies
exist between self-reported and proper clinically diagnosed CMA [2–4]. As with most other allergies,
CMA has a complex and heterogeneous clinical presentation. The heritability of CMA is estimated at
15%, which, when compared to other (food) allergies, represents a moderate genetic component [5,6].
Although most young children develop tolerance for cow’s milk proteins within a few years, these
children seem to have an increased risk for developing other diseases involving a hypersensitive
immune system, including asthma and inflammatory bowel disease (IBD) [6–10], which may suggest
Nutrients 2018, 10, 1582; doi:10.3390/nu10111582 www.mdpi.com/journal/nutrients
Nutrients 2018, 10, 1582 2 of 12
common genetic pathways between these diseases. While several genome-wide surveys on asthma,
allergic rhinitis (AR) and atopic dermatitis (AD) have been reported, genome-wide association
studies (GWAS) of food allergy (FA) are currently still limited [11–14]. Recently, we reported a
candidate-gene association study in CMA-children and matched controls [15]. Although the results
of the latter study favoured the “Allergic March” hypothesis, the number of studied variants was
limited and the specific direction of the allergic march was narrowly defined [11,16]. Asthma, AD, and
rheumatoid arthritis (RA) have previously been suggested to be related to CMA [17,18]. In addition
to these immunological hypersensitivity related disorders, human studies also revealed a clear link
between autism spectrum disorder (ASD) and asthma, and related immunological sensitivities which
strongly suggest that allergic diseases are common in patients with ASD [19,20]. In 2013 Theoharides
suggested that activation of brain mast cells and immune factors are associated with behavioural and
language development, which may lead to focal immune reactions in the brain and subsequent focal
encephalitis [21].
Large-scale GWAS studies have identified large numbers of single nucleotide polymorphisms
(SNPs) related to behavioural and disease-related traits [22]. Moreover, studies have shown that the
vast majority of these traits are highly polygenic, showing evidence of a complex genetic architecture
composed of many genetic variants of low individual effect. However, the variability that can be
explained by results from current GWAS studies is much lower than the actual heritability of these
traits, commonly referred to as the ‘missing heritability’ [23]. Despite a large gap between variance
explained by GWAS and the total variance of the trait, it has been shown that marginally significant
SNPs that do not reach genome-wide significance (P < 5 × 10−8) contribute to the explained variance
in the trait [24]. The genetic signals of these sub-threshold markers can be collectively captured by
a polygenic risk score (PRS) that includes significant and non-significant markers, quantifying the
genome-wide genetic predisposition of an individual for a specific trait [25,26]. In addition, such a
genome-wide score analysis can also be used to study a shared genetic susceptibility across traits
and diseases.
In this study, we explore the contribution of common genetic variants associated with asthma,
ASD, AD, IBD, and AR, captured by PRS, to patients that have suffered from CMA by comparing
the PRSs of CMA children with the PRS of healthy controls. Secondly, using six-year follow-up data
from these children we aim to link the PRS for these traits to phenotypes related to asthma, AR and
AD. Put together, the results of this study may provide new insight into a possible shared genetic
architecture between CMA and these traits.
2. Methods
Sample collection: In this study, we included 22 children, suffering from CMA at intake and
participating in the Dutch EuroPrevall Birth Cohort study. All 22 children became cow’s milk tolerant
within a time frame of two years after diagnosis. The EuroPrevall study is described in detail in
Supplementary File S1 and previously by others [4,27,28]. Follow-up data of the Dutch EuroPrevall
Birth Cohort study were acquired between 2015 and 2016, when the children reached the age of
approximately six years old. The follow-up study involved questionnaires regarding (food) allergy
related symptoms and, when indicated, further medical examination. Prospective data were obtained
for symptoms indicating (1) asthma: wheezing, dyspnoea, (nightly) coughing, clinically diagnosed
asthma and asthma medication use over the last 12 months, (2) allergic rhinitis (AR): permanent
irritated nasal mucosa, burning sensation of the eyes, clinically diagnosed AR and use of AR medication
over the last 12 months, (3) atopic dermatitis (AD): eczema and the (cutaneous) use of topical steroids,
and (4) any food allergy. The present study only focused on the questionnaire outcomes related to
asthma, AR and AD and their clinical diagnosis and/or the use of anti-allergy medication. Complete
follow-up data was available for 19 former CMA patients. The selection of this subset of CMA cases
was done irrespective of health status, i.e., no information of the above described health status was
available at the time of genotyping.
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All children described in our manuscript are participating in the Dutch EuroPrevall birth cohort
study. The Medical Ethics Committee of the AUMC approved the Dutch EuroPrevall Birth Cohort
Study (METC 2006/005 and METC prospective data 2014/056). Written informed consent, for both
the study and genetic sampling, was obtained from both parents of each child, unless only one of
them had parental rights. Within the context of a reference group, we selected 307 anonymous famine
unexposed controls from the “Dutch Famine cohort”. The subjects of this reference set were, like our
CMA cases, born in the vicinity of Amsterdam, The Netherlands, and born in the period between
1946 and 1947, sampled over the last two decades. This reference set is assumed to represent the
general Dutch population rather than screen negatives for any studied trait in this study. According
previous reports on the Dutch Famine cohort, we assumed for allergies and related phenotypes, that
this reference set reflects the general prevalence’s in the Dutch population [29] For the reference set,
the Medical Ethics Committee of the AUMC approved the study (METC 2001/215) and a written
informed consent was obtained for each participant [29,30].
Genotyping, quality control, and genotype imputation and polygenic scoring: amplified genomic
(see Supplementary File S1) and genomic DNA of patients and reference set, respectively, were
submitted for microarray-based genotyping at GenomeScan B.V. (Leiden, The Netherlands), using the
Affymetrix Axiom UKB WCSG-96 array (Santa Clara, CA, USA). Imputation of the cleaned genotype
dataset was performed using IMPUTE2 [31]. PRSs were calculated based on genome-wide association
(GWAS) results for the following five traits: (1) Asthma, reported by Moffatt et al. in 2010 [32], (2)
ASD, reported by the Cross-Disorder Group of the Psychiatric Genomics Consortium in 2013 [33],
(3) AD, reported by Paternoster et al. in 2015 [13], (4) IBD, reported by Liu et al. in 2015 [34] and (5)
RA reported by Stahl et al. in 2010 [35]. In order to evaluate the optimal P-value threshold (PT ) for
discriminating cases and the reference set, we calculated additive PRSs on a broad range of P-value
thresholds for SNP inclusion (PT < 0.001, PT < 0.005, PT < 0.01, PT < 0.05, PT < 0.1, PT < 0.5, and PT < 1).
Polygenic scores were calculated by multiplying the number of risk alleles (0, 1, 2) by the SNP effect
size (beta or log-transformed odds ratio). This study aims to detect genetic predisposition for several
other adverse immunological outcomes after suffering from cow’s milk allergy per se, in relation
to the general Dutch population. In this context, the age difference between cases and control was
assumed not to be a limiting factor and we considered the reference set in this study to be appropriate.
Prior to statistical analyses, PRS values were standardized to a mean of 0 and standard deviation of 1.
In this study, we analysed common variants, implying that after this standardization the risk alleles
in the reference set would be normally distributed centred around 0. In the former CMA patients,
for any trait analysis, a deviation of the mean from 0 indicates enrichment of risk alleles. Detailed
descriptions of genotyping, quality control, imputation, polygenic risk scoring and further statistical
analyses can be found/have been included in Supplementary File S1. Genotypes of the used SNPs,
including imputation score (RSQ), of all included cases and the reference set and the appropriate
meta-data that were used in this study are available on reasonable request and, according to the Dutch
privacy law, only after a data transfer agreement.
3. Results
Genotype sample: The mean call rates in CMA cases and the reference set were 97.1% and 97.7%
respectively (Table 1). Although in both the cases and the reference set we observed a single sample with
a call rate lower than 95%, subsequent data evaluation did not show any other deviation of standard
(GenABEL) SNP array quality checks in these samples. Therefore, no samples were excluded in further
analyses. Imputation to the 1000 Genomes reference panel (phase1, v3 (20101123, GRCh37 / hg19) yielded
27,507,174 genetic variants. Post-imputation quality control, based on minor allele frequency (MAF > 0.01)
and INFO score (INFO > 0.9), yielded a total number of 6,932,124 variants present in all samples which
were available for calculating PRS.
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Table 1. Characteristics cow’s milk allergic children (CMA) and the reference set.
Genotype Data N Female Male Age CR (mean) CR (min) CR (max)
CMA 22 6 16 11.8 ± 4.9 * 97.1% 93.0% 98.0%
Reference set 307 130 177 53.3 ± 0.58 ** 97.7% 94.0% 99.0%
* Mean age ± Standard deviation (months) at blood drawing. ** Mean age ± standard deviation (years) at blood
drawing. CR: call-rate.
Polygenic risk scores (PRS): PRS analyses on imputed genotype data of CMA and the reference
set were performed using SNP sets obtained for each trait. The number of SNPs that entered each
PRS analysis is described in Table S1. We observed a significantly higher PRS in CMA cases compared
to the reference set for all SNP set P-value thresholds for asthma, with the exception of the P-value
threshold of PT < 0.005 that showed a similar direction of effect, but did not yield a significant
differential association (Figure 1, Table 2). The two largest mean asthma PRS differences (δ) between
cases and the reference set were observed for the P-value thresholds PT < 0.005 (δ = 0.41, OR = 1.50,
95% CI = 0.98–2.32, P = 0.065) and PT < 0.01 (δ = 0.58, OR = 1.85 95% CI = 1.16–2.94, P = 0.009) (Figure 1,
Table 2). For the ASD PRS, we observed a significantly higher PRS for the SNP set PT < 0.001 in CMA
cases compared to the reference set. However, for all other ASD SNP sets we found opposite trends
in CMA cases of which the PRS SNP set PT < 0.1 was significantly lower (P = 0.001) in CMA patients
compared to the reference set (Figure 1). Although we found no significant differences between cases
and the reference set for all PT thresholds of the AD PRS analyses, our analyses showed a consistent
trend to a negative PRS in CMA cases compared to the reference set. Similar findings were observed
for Inflammatory bowel disease SNP sets, consistently showing lower PRS in CMA cases than in
the reference set (Figure 1, Table 2), although not reaching significance. Finally, for RA we observed
suggestively higher PRS in CMA patients compared to the reference set, with the exception of the
largest SNP set of PT < 1 (Figure 1, Table 2).
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Figure 1. Polygenic risk scoring (weighted) for hypersensitive immune disorders asthma, autism 
spectrum disorder, atopic eczema, inflammatory bowel disease and allergic rhinitis (Prism 5.01, 2007). 
C: represents PRS in controls (N = 307), CMA represent PRS in (former) cow’s milk allergic children 
(N = 22). (A) PRS scoring with (GWAS) cutoff of PT < 0.001, (B) PRS scoring with (GWAS) cutoff of PT 
< 0.005, (C) PRS scoring with (GWAS) cutoff of PT < 0.01, (D) PRS scoring with (GWAS) cutoff of PT < 
0.05, (E) PRS scoring with (GWAS) cutoff of PT < 0.1, (F) PRS scoring with (GWAS) cutoff of PT < 0.5 
and (G) PRS scoring with (GWAS) cutoff of PT < 1. Parametric test (t-test) was performed to test for 
differences in means of the PRS between former CMA patients and healthy controls. We assumed a P 
< 0.05 statistically significant. 
Figure 1. Polygenic risk scoring (weighted) for hypersensitive immune disorders asthma, autism
spectrum disorder, atopic eczema, inflam atory bo el disease and allergic rhinitis (Prism 5.01, 2007).
C: represents PRS in controls (N = 307), C represent P S in (former) cow’s milk allergic children
(N = 22). (A) PRS sc ri ith (GWAS) cutoff of PT < 0.001, (B) PRS scoring with (GWAS) cutoff
of PT < 0.005, (C) PRS scoring with (GWAS) cutoff of PT < 0.01, (D) PRS scoring with (GWAS) cutoff
of PT < 0.05, (E) PRS scoring with (GWAS) cutoff of PT < 0.1, (F) PRS scoring with (GWAS) cutoff of
PT < 0.5 and (G) PRS scoring with (GWAS) cutoff of PT < 1. Parametric test (t-test) was performed
to test for differences in m ans of the PRS between former CMA patients a d healthy controls. We
assumed a P < 0.05 tatisti ally significant.
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Table 2. Odds ratios polygenic risk score (PRS) analyses.
PRS Analysis Asthma ASD AD IBD RA
PT < 0.001
1.79 (1.14–2.84),
0.012
1.59 (1.04–2.44),
0.032
0.82 (0.53–1.28),
0.383
0.82 (0.53–1.28),
0.383
0.82 (0.53–1.28),
0.383
PT < 0.005
1.50 (0.98–2.32),
0.065
0.85 (0.55–1.32),
0.481
0.86 (0.56–1.32),
0.483
0.86 (0.56–1.32),
0.483
0.86 (0.56–1.32),
0.483
PT < 0.01
1.85 (1.16–2.94),
0.009
0.83 (0.54–1.28),
0.410
0.94 (0.61–1.45),
0.780
0.94 (0.61–145),
0.780
0.94 (0.61–1.45),
0.780
PT < 0.05
1.73 (1.13–2.27),
0.012
0.73 (0.47–1.13),
0.161
0.89 (0.58–1.37),
0.596
0.89 (0.58–1.37),
0.596
0.89 (0.58–1.37),
0.596
PT < 0.1
1.74 (1.13–2.66),
0.012
0.45 (0.28–0.74),
0.002
0.77 (0.50–1.18),
0.231
0.77 (0.50–1.18),
0.231
0.77 (0.50–1.18),
0.231
PT < 0.5
1.74 (1.13–2.66),
0.011
0.67 (0.43–1.05),
0.078
1.42 (0.91–2.23),
0.124
1.42 (0.91–2.23
), 0.124
1.42 (0.91–2.23),
0.124
PT < 1
1.73 (1.13–2.65),
0.012
0.67 (0.43–1.04),
0.074
1.17 (0.76–1.81),
0.479
1.17 (0.76–1.81),
0.479
1.17 (0.76–1.81),
0.479
Odds ratio and the corresponding 95% confidence interval (95% CI) and corresponding P-value for all PRS analyses
(logistic regression) based on standardized PRS values representing the effect for one standard deviation change in
PRS. ASD: autism spectrum disorder; AD: atopic dermatitis; IBD: inflammatory bowel disease; RA: rheumatoid
arthritis. P-values < 0.05 were assumed significant, annotated in bold.
Association of PRS with follow-up allergy related traits: Characteristics of the subset of CMA
patients (N = 19, six females), obtained when they were around six years of age, are described in
Table 3. In general, the highest incidence we observed concerned asthma-related and AD-related
symptoms. In the latter context, we observed that diagnosed asthma, asthma medication use, AD and
the use of topical steroids at the age of six years were present in one third of the former CMA patients
(Table 3). Next, we performed association analysis on each symptom within the four prospective
allergic disorder symptom groups, i.e., on asthma, AR, AD, and FA. Since our sample size was small,
we limited the number of tests and performed these analyses only for a subset of the PRS outcomes,
namely for asthma PT < 0.001 and PT < 1 and for ASD PT < 0.001 and PT < 0.01. We assumed that
allergic disorders, as obtained in the prospective data, are not independent of each other, therefore, we
assumed associations with a nominal P-value < 0.05 as significant. For the asthma PRS PT < 0.001, we
observed a positive PRS associated with nightly coughing (P = 0.02, Figure 2A and Table S2). However,
it should be noted that both dyspnoea and clinical diagnosed asthma also showed a trend of a higher
PRS. For all asthma PRS scores, with exception of PT < 0.005, we have detected a significantly higher
PRS in former CMA patients. In order to address the other end of the spectrum of SNP sets, we
additionally analysed the asthma extreme SNP set of PT < 1. Although not significant, this association
showed similar trends with regard to the average PRS scores for the significantly associated symptoms
in the asthma PRS PT < 0.001. Furthermore, one of CMA patients that showed a positive IgE level
within the first 2.5 years lifespan (Table 3) showed a value >1 for all the asthma PRSs, while the other
IgE positive patient showed merely negative values. We observed that dyspnoea, nightly coughing
and diagnosed asthma showed relatively high average PRS of 1.0, 1.0, and 0.8, respectively (Figure 2B
and Table S2).
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chronically irritated eyes, allergic rhinitis clinically diagnosed, Allergic rhinitis medication (past 12 
months), (iii) atopic dermatitis: eczema; topical steroids use (past 12 months), (iiii) food allergy. (A) 
Asthma PRS scoring with (GWAS) cutoff of PT <0.001 and (B) asthma PRS scoring with (GWAS) cutoff 
of PT < 1. (C) ASD PRS scoring with (GWAS) cutoff of PT < 0.001 and (D) ASD PRS scoring with (GWAS) 
cutoff of PT < 0.01. ANOVA was performed to test for differences in means of the PRS between CMA 
patients scored for particular symptom or not. Red indicates no, green indicates yes.  We assumed a 
P < 0.05 statistically significant. 
Table 3. Six year follow-up characteristics former CMA patients. 
General  
Total (N) 19 
Female (N) 6 
Male (N) 13 
Age (mean ± SD) 7.0 ± 1.0 * 
2 year IgE positive ** 2 
Asthma related N (%) 
Wheezing 4 (21.1%) 
Dyspnoea 4 (21.1%) 
Coughing at night  5 (26.3%) 
Asthma diagnosed 6 (33.3%) 
Asthma medication 6 (33.3%) 
Allergic rhinitis related  N (%) 
Irritated nasal mucosa) 6 (33.3%) 
Eyes 3 (15.8%) 
Allergic rhinitis diagnosed 1 (5.3%) 
Figure 2. Polygenic risk scoring (weighted) for hypersensitive immune disorders asthma and
autism spectrum disorder in relation to (prospectively obtained) hypersensitive immunological traits
(Prism 5.01, 2007): (i) asthma related: wheezing; dyspnoe, (nightly) coughing; asthma clinically
diagnosed; asthma medication (past 12 months), (ii) allergic rhinitis related: chronically irritated nasal
mucosa, chronically irritated eyes, allergic rhinitis clinically diagnosed, Allergic rhinitis medication
(past 12 months), (iii) atopic dermatitis: eczema; topical steroids use (past 12 months), (iiii) food allergy.
(A) Asthma PRS scoring with (GWAS) cutoff of PT <0.001 and (B) asthma PRS scoring with (GWAS)
cutoff of PT < 1. (C) ASD PRS scoring with (GWAS) cutoff of PT < 0.001 and (D) ASD PRS scoring
with (GWAS) cutoff of PT < 0.01. ANOVA was performed to test for differences in means of the PRS
between CMA patients scored for particular symptom or not. Red indicates no, green indicates yes. We
assumed a P < 0.05 statistically significant.
Table 3. Six year follow-up characteristics former CMA patients.
General
Total (N) 19
Female (N) 6
Male (N) 13
Age (mean ± SD) 7.0 ± 1.0 *
2 year IgE positive ** 2
Asthma related N (%)
Wheezing 4 (21.1%)
Dyspno a 4 (21.1%)
Coughing at night 5 (26.3%)
Asthma diagnosed 6 (33.3%)
Asthma medication 6 (33.3%)
Allergic rhinitis related N (%)
Irritate nasal mucosa) 6 (33.3%)
Eyes 3 (15.8%)
Allergic rhinitis diagnosed 1 (5.3%)
Allergic rhinitis medication 5 (26.3%)
Nutrients 2018, 10, 1582 8 of 12
Table 3. Cont.
General
Atopic dermatitis related N (%)
Eczema 7 (36.8%)
Topical steroids 6 (31.6%)
Allergy related N (%)
Food allergy 3 (15.8%)
* Mean age ± Standard deviation (years) at the time of the follow study. ** Number of CMA patients that became
IgE positive (IgE < 0.35 kU/L) during the first 2.5 years of life, data on IgE levels was available for 16 of 19 former
CMA patients.
For ASD we selected P-value thresholds that were significant (PT < 0.001 and PT < 0.01) to test for
association with prospective data. For the PRS based on PT < 0.001, we observed significant association
with nightly coughing (P = 0.05) and a trend (P = 0.07) with clinical diagnosed asthma (Figure 2C and
Table S3). The PRS in the former CMA cases using the threshold of PT < 0.001 showed positive associations,
while in all other P-value thresholds we observed protective associations of the scores (negative δ). In the
prospective data analyses, we found no evidence of any association of the PRS obtained from the SNP set
of PT < 0.01 with any symptom of the four disorders (Figure 2D and Table S3).
4. Discussion
To date, literature on the genetic architecture of common variants underlying CMA is limited to
candidate gene/variant approaches, and the present study is the first to describe cross-trait association
between a large number of common variants and CMA. Despite the fact that genome-wide surveys
are absent and, therefore, the specific genetic architecture of CMA remains unclear, the phenotypic
relation with other types of allergy have been studied widely [11,15,36]. Recently, our group and
others have hypothesized that food allergy susceptibility, including CMA, involves an epigenetic
component as well [37,38]. The latter hypothesis was strengthened by the fact that a genetic component
cannot explain the vast increase of food allergy prevalence world-wide [7]. The way food is currently
processed in comparison to the pre-industrialization period has been hypothesized to involve exposure
to new antigens that might underlie the recent observed increase in allergic sensitization(s) [39].
On the other hand, it should be noted that clinical diagnosis of food allergies has also been
improved dramatically over the last decades, which may have resulted in substantial lower number
of misdiagnosis and, thus, an improved estimate of its prevalence. Moreover, given the fact that
nowadays food allergy has been acknowledged as a public health issue, its diagnosis has become
common practice compared to 50+ years ago, which probably also contributed to the increase of food
allergies prevalence [40,41]. Furthermore, without excluding an epigenetic component contributing to
the expression of food allergy, the genetic component especially for CMA might very well resemble or
overlap with the genetic component of other more common types of later onset allergies, and might,
therefore, represent a strong predictor for later onset hypersensitive immune disorders.
Phenotypically, this phenomenon has been very well covered by the “allergic march” hypothesis,
which was recently studied extensively by Alduraywish et al. [42]. Genetic mechanisms underlying
their observations were addressed in the present study, using PRS that included common variants
detected in/for other types of hypersensitive immune disorders: asthma, AR and AD. Moreover,
the use of prospective data on allergy and allergic symptoms in our CMA cohort can be considered as
validation tool of our findings with regard to the risk of these later onset allergies. In this context, we
were able to detect consistent significantly higher PRSs for asthma for virtually all SNP P-value
thresholds compared to the reference set, but not for AR or AD. Moreover, our asthma based
findings reflected relatively high odds ratios for these PRS. These findings strongly suggest that
the genetic predisposition for later onset of asthma in children with a history of CMA involves a strong
overlapping genetic component that is not reflected by positive IgE plasma levels within the first
2.5 years. In order to validate these findings on the asthma PRS analyses, the availability of prospective
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data is essential. Our former CMA patients were followed up after approximately six years. The timing
of this follow-up with regard to the manifestation of asthma or asthmatic symptoms is in line with
earlier reports on disease onsets covered by the allergic march hypothesis [42].
Although we cannot conclude that asthma and asthma-related symptoms are more common
in former CMA patients (i.e., we did not include CMA screen negatives in this context), our data
does indicate that the genetic load of asthma associated common variants is enriched in the former
CMA patients that suffer from asthma and asthma-related phenotypes. In the context of a potential
prediction of later onset asthma in CMA patients, our symptom association results, obtained with the
P-value threshold of PT < 0.001, are substantial. All former CMA cases that were diagnosed at a later
age with asthma and/or reported nightly coughing and/or dyspnoea showed, without exception,
relatively high PRS scores. The delta mean PRS difference between these patients was for dyspoea
(δ = 0.74), for nightly coughing (δ = 0.88) and for asthma (δ = 0.68). A considerable number of former
CMA patients showed a high PRS, but showed so far not (yet) any asthmatic symptoms. Whether
these patients will develop asthmatic symptoms at a later age, should be monitored in additional
follow-up studies. In case such follow-ups report that these high PRS former CMA patients do develop
symptoms, this would result in a strong specificity measure as well, implying that genetic profiling of
CMA patients may be a powerful tool in predicting asthmatic symptoms in later life, possibly leading
to preventive interventions in the future.
Accumulating evidence shows that a hypersensitive immune system, reflected by asthma or
allergies, is associated with ASD [20]. Moreover, gastrointestinal dysfunction has also been associated
with autoimmunity and ASD [19]. At the same time, gastrointestinal dysfunction, reflected for example
by IBD, in relation to asthma has also been previously described [43]. In order to further explore this
possible shared genetic component between allergies, asthma, ASD and IBD in our study, we performed
additional PRS analyses based on/using SNP sets obtained from recently published ASD and IBD
GWAS [34]. Our results yielded suggestive evidence of a shared genetic component of the smallest
SNP set (PT < 0.001) of ASD in former CMA patients. Surprisingly, the other ASD P-value threshold,
especially PT < 0.01, showed an opposite effect, reflecting an ASD favorable genetic component in
former CMA patients (Figure 2C,D, Table S3). Although we cannot rule out the possibility that only a
(small) subset of risk alleles may indeed be shared in CMA and ASD, these conflicting observations
should be interpreted with caution. Further discussion on limitations and strengths of our study are
described in Supplementary File S1.
Future studies should aim to include larger samples of CMA cases, which allow sufficient
statistical power to uncover the genetic architecture of CMA. Identification of variants and genes related
to CMA may aid in identifying overlapping risk loci between CMA, allergies and immune-related
traits. In conclusion, to the best of our knowledge, this is the first study to investigate polygenic risk
scores and cross-trait genetic liability in CMA patients, using genome-wide SNP sets from GWAS on
immune-related traits. Our PRS analyses in former CMA patients show a significantly higher PRS of
immune-related traits in patients compared to the reference set and, thus, a shared genetic susceptibility
of CMA and asthma and asthmatic symptoms. Moreover, on the basis of the prospective data in our
former CMA patients, we found a strong indication that our PRS of asthma might contribute to an
accurate prediction of later onset asthma in these patients. Improving insight into the link between
genetic predisposition for immune-related traits/disorders might lead to early clinical intervention in
order to prevent the manifestation of asthma or limit its severity later in life.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/11/1582/s1,
Supplementary File S1: supplementary methods and supplementary discussion, Table S1. Number of included SNPs
(MAF > 0.01) in polygenic risk score (PRS) analyses, Table S2: Association analyses of asthma P < 0.001 and P < 1
polygenic risk score (PRS) per follow-up symptom outcome, Table S3: Association analyses of autism P < 0.001 and
P < 0.1 polygenic risk score (PRS) per follow-up symptom outcome.
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